Free Trial
LON:CREO

Creo Medical Group (CREO) Share Price, News & Analysis

Creo Medical Group logo
GBX 19.53
-0.10 (-0.50%)
(As of 11/1/2024 12:39 PM ET)

About Creo Medical Group Stock (LON:CREO)

Key Stats

Today's Range
19.50
20
50-Day Range
19.52
32.50
52-Week Range
19
50
Volume
274,713 shs
Average Volume
654,507 shs
Market Capitalization
£70.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for flexible endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device designed for soft tissue ablation; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the GI tract; ScopeClip, a single-use rotational and repositionable hemoclips; ScopeBite, a portfolio of biopsy forceps; ScopeGrasp, a portfolio of grasping forceps; and ScopeInject, an injection needle. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.

Receive CREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Creo Medical Group and its competitors with MarketBeat's FREE daily newsletter.

CREO Stock News Headlines

True paradigm shift
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

CREO Stock Analysis - Frequently Asked Questions

Creo Medical Group's stock was trading at GBX 46 at the beginning of the year. Since then, CREO stock has decreased by 57.6% and is now trading at GBX 19.53.
View the best growth stocks for 2024 here
.

Creo Medical Group PLC (LON:CREO) released its quarterly earnings results on Wednesday, September, 23rd. The company reported ($6.00) EPS for the quarter. Creo Medical Group had a negative trailing twelve-month return on equity of 38.49% and a negative net margin of 73.93%.

Shares of CREO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Creo Medical Group investors own include Aviva (AV), IQE (IQE), Lloyds Banking Group (LLOY), Barclays (BARC), BP (BP), BT Group (BT.A) and Coats Group (COA).

Company Calendar

Last Earnings
9/23/2020
Today
11/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
279
Year Founded
N/A

Profitability

Net Income
£-22,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£30.30 million
Cash Flow
GBX 8.03 per share
Book Value
GBX 13 per share

Miscellaneous

Free Float
N/A
Market Cap
£70.64 million
Optionable
Not Optionable
Beta
0.86
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (LON:CREO) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners